ENERGYNEST
Tata Steel operates one of Europe’s largest steel production facilities in IJmuiden / Netherlands. Currently, large energy potentials are released to the atmosphere, through intermittent high temperature exhaust gases. Implicit economic benefits of this waste heat remain untapped. Finding an effective way to recover and reuse this energy will not only yield attractive economic returns, but also significant CO2 emission reductions.
In order to fully utilize such effects, Tata Steel is now commencing the implementation of an EnergyNest Thermal Energy Storage (TES) demo project as a ‘lighthouse initiative’. The IJmuiden demo will utilize exhaust gas energy from steel production to cover own energy demands in the facility – resulting in reduced natural gas consumption and CO2 emissions.
“The steel industry has already undertaken huge efforts to reduce emissions, and to go any further simply requires new technologies. This demo installation is just a first step for Tata’s IJmuiden plant. We are proud to be yet again the global leader for implementing environmentally friendly solutions with a strong business case.” says Gerard Jägers, Program Manager Energy Efficiency. A joint assessment of effects for a full-scale implementation of the EnergyNest throughout the IJmuiden facility shows impressive results: a 500 MWh TES can yield annual savings of 2.3 million GJ of natural gas (65 million Nm3 ) and 130.000 tons of emitted CO2 . EnergyNest CEO Dr. Christian Thiel: “These savings compensate for annual CO2 emissions of 90.000 cars. And at the same time a full-scale implementation offers extremely attractive economics, which supplement such a project with a very healthy business rationale. We are very proud to support Tata Steel in its game-changing approach towards carbon footprint reduction.”
The EnergyNest TES technology is based on globally available materials that are fully recyclable. Due to its very low cost-base, a full-scale implementation in the IJmuiden facility – together with Jord as acting EPC – has a payback of less than three years, based on today’s natural gas prices. Should natural gas prices increase the payback period is reduced to less than two years. Adopting this innovative technology, Tata Steel IJmuiden will strengthen the facility's status as a global technology frontrunner.
About EnergyNest: EnergyNest (EN) is a technology company based in Billingstad, close to the Norwegian capital Oslo. Founded in 2011, EN has developed a unique and patented design for a modular solid-state thermal energy storage (“TES”) systems and a tailored solid state storage medium (HEATCRETE®) that enables a very simple, efficient, and low cost energy storage system (“EN technology”). The EN technology can be applied in various market segments, that require high temperature thermal energy storage for many hours or days. EN’s technology is field proven at the Masdar Institute, UAE.
About Tata Steel: Tata Steel is one of the world leading manufacturers of raw steel, rolled and coated products. It is also one of the world’s most geographically diversified steel producers, serving many demanding markets worldwide, including Aerospace, Automotive, Construction, Consumer Products, Defence & Security, Energy & Power, Lifting & Excavating and Packaging. Tata Steel is committed to the design of more sustainable products that contribute to solutions, which are lighter, last longer and use fewer resources to produce.
About Jord: Jord Oil & Gas Systems B.V. is a Rotterdam based company that designs, manufactures, commissions, and services custom-engineered process equipment, modular skids, and turnkey plants for the steel, oil and gas, chemical and petrochemical industries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005611/en/
Contact:
EnergyNest
Thomas Palkovich
Commercial Director
Mob:
+47 982 08 384
Email: tp@energy-nest.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom